The Venture Codex Logo

The Venture Codex

Cambrian Biopharma

228 Park Avenue South Suite 66643, New York, NY, 10003, United States

Overview

Developing therapeutics to lengthen healthspan and modernize healthcare.

Founded

2019

Deals ยท 12mo

0

Links

WebsiteLinkedInX (Twitter)

Stage focus

Series A
Series B
Series C

Geographic focus

United States

Sector focus

Biopharma
Biotechnology
Life Science

Investment portfolio

4rounds
NAMEDATESIZE
Vita Therapeutics
Oct 2022Led
$31 MSeries B
Vita Therapeutics
Jun 2021Led
$32 MSeries A
Arcellx
Apr 2021Participated
$115 MSeries C
Sensei Biotherapeutics
Jan 2021Participated
$30 MSeries B
Vita Therapeutics
Oct 2022Led
$31 MSeries B
Vita Therapeutics
Jun 2021Led
$32 MSeries A
Arcellx
Apr 2021Participated
$115 MSeries C
Sensei Biotherapeutics
Jan 2021Participated
$30 MSeries B
4
Items
Browse all public portfolio deals

Insights

Time horizon

View by

Deal Distribution

Cambrian Biopharma: 4 funding rounds are recorded in the selected participation categories.All available history.
Cambrian Biopharma: 4 funding rounds are recorded in the selected participation categories. All available history
Round typeLed dealsParticipated deals
Series A10
Series B11
Series C+01

Monthly Deal Activity

Cambrian Biopharma: 4 deals are recorded across 70 months.All available history.
Cambrian Biopharma: 4 deals are recorded across 70 months. All available history
MonthDeals
Jan '211
Feb '210
Mar '210
Apr '211
May '210
Jun '211
Jul '210
Aug '210
Sep '210
Oct '210
Nov '210
Dec '210
Jan '220
Feb '220
Mar '220
Apr '220
May '220
Jun '220
Jul '220
Aug '220
Sep '220
Oct '221
Nov '220
Dec '220
Jan '230
Feb '230
Mar '230
Apr '230
May '230
Jun '230
Jul '230
Aug '230
Sep '230
Oct '230
Nov '230
Dec '230
Jan '240
Feb '240
Mar '240
Apr '240
May '240
Jun '240
Jul '240
Aug '240
Sep '240
Oct '240
Nov '240
Dec '240
Jan '250
Feb '250
Mar '250
Apr '250
May '250
Jun '250
Jul '250
Aug '250
Sep '250
Oct '250
Nov '250
Dec '250
Jan '260
Feb '260
Mar '260
Apr '260
May '260
Jun '260
Jul '260
Aug '260
Sep '260
Oct '260

Sector Breakdown

Cambrian Biopharma: Health & Life Sciences is the largest displayed sector by deal count (4 deals).All available history.

A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.

Cambrian Biopharma: Health & Life Sciences is the largest displayed sector by deal count (4 deals). All available history
SectorDeals
Health & Life Sciences4

Deal Size Distribution

Cambrian Biopharma: 4 rounds have a disclosed size in the displayed size bands.All available history.

Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.

Cambrian Biopharma: 4 rounds have a disclosed size in the displayed size bands. All available history
Round size band (USD)Deals
<$5M0
$5M-$10M0
$10M-$25M0
$25M-$50M3
$50M-$100M0
$100M-$250M1
$250M-$500M0
$500M-$1B0
$1B+0

Deals By Geography

Cambrian Biopharma: United States has the largest recorded deal count among the displayed regions (4 deals).All available history.

Top 1 of 1 regions; European countries are grouped as Europe.

Cambrian Biopharma: United States has the largest recorded deal count among the displayed regions (4 deals). All available history
RegionDeals
United States4
Cambrian Biopharma: 20 co-investors are shown, with Adage sharing 1 recorded deals.All available history.

Co-Investors

Bubble size = shared deals

Click a bubble to open that fund in a new tab.

Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.

Cambrian Biopharma: 20 co-investors are shown, with Adage sharing 1 recorded deals. All available history
Co-investorShared deals
Adage1
Apeiron Investment Group1
Asymmetry Ventures1
CaaS Capital Management1
CAM Capital1
Catalio Capital Management1
Cedars-Sinai Medical Center1
Clough Capital Partners1
Early Light Ventures1
Future Ventures1
Kiwoom Bio1
LG Tech1
Moore Strategic Ventures1
New Enterprise Associates1
Novo Holdings1
Presight Capital1
Pura Vida Investments1
Riptide Ventures1
Samsara BioCapital1
SCM Life Sciences1

Investment Strategy

Cambrian Biopharma: Led accounts for 50% and participating for 50% of round participation.All available history.
Cambrian Biopharma: Led accounts for 50% and participating for 50% of round participation. All available history
CategoryDeals (count)Share (%)
Led250%
Participating250%
Cambrian Biopharma: Single-lead accounts for 50% and co-led for 50% of lead dynamics.All available history.
Cambrian Biopharma: Single-lead accounts for 50% and co-led for 50% of lead dynamics. All available history
CategoryDeals (count)Share (%)
Single-lead150%
Co-led150%

Team

Adrienne Hallett

Vice-President of Global Policy

Christian Angermayer

Co-Founder

James Peyer

Founder and CEO

Ruth Thieroff-Ekerdt

EVP, Clinical Development